Hypertension and concurrent arrhythmias

Federico Lombardi, Paolo Terranova

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Hypertension and cardiac arrhythmias commonly coexist in many patients. In this review, we will initially discuss arrhythmogenesis in hypertension, with particular emphasis on atrial and ventricular tachyarrhythmias and sudden cardiac death, whilst in the final part, we will focus our attention on the effects of anti-hypertensive therapies on supra-ventricular and ventricular arrhythmias and on sudden cardiac death prevention. Many patients with atrial fibrillation or frequent premature ventricular contractions have hypertension, and both need to be managed appropriately. Furthermore, hypertensive left ventricular hypertrophy could cause a wide variety of ventricular arrhythmias, which could end in sudden cardiac arrest. Most anti-hypertensive therapies, such as the β-blockers or ACE inhibitors, by slowing or interrupting the progression towards atrial and ventricular remodelling might exert some anti-arrhythmic effect, thus reducing the risk of sudden cardiac death in these patients.

Original languageEnglish
Pages (from-to)1703-1713
Number of pages11
JournalCurrent Pharmaceutical Design
Volume9
Issue number21
DOIs
Publication statusPublished - 2003

Fingerprint

Sudden Cardiac Death
Cardiac Arrhythmias
Hypertension
Antihypertensive Agents
Atrial Remodeling
Ventricular Remodeling
Ventricular Premature Complexes
Anti-Arrhythmia Agents
Left Ventricular Hypertrophy
Angiotensin-Converting Enzyme Inhibitors
Tachycardia
Atrial Fibrillation
Therapeutics

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Hypertension and concurrent arrhythmias. / Lombardi, Federico; Terranova, Paolo.

In: Current Pharmaceutical Design, Vol. 9, No. 21, 2003, p. 1703-1713.

Research output: Contribution to journalArticle

Lombardi, Federico ; Terranova, Paolo. / Hypertension and concurrent arrhythmias. In: Current Pharmaceutical Design. 2003 ; Vol. 9, No. 21. pp. 1703-1713.
@article{411e563a44f34d66802622c34ae6e41b,
title = "Hypertension and concurrent arrhythmias",
abstract = "Hypertension and cardiac arrhythmias commonly coexist in many patients. In this review, we will initially discuss arrhythmogenesis in hypertension, with particular emphasis on atrial and ventricular tachyarrhythmias and sudden cardiac death, whilst in the final part, we will focus our attention on the effects of anti-hypertensive therapies on supra-ventricular and ventricular arrhythmias and on sudden cardiac death prevention. Many patients with atrial fibrillation or frequent premature ventricular contractions have hypertension, and both need to be managed appropriately. Furthermore, hypertensive left ventricular hypertrophy could cause a wide variety of ventricular arrhythmias, which could end in sudden cardiac arrest. Most anti-hypertensive therapies, such as the β-blockers or ACE inhibitors, by slowing or interrupting the progression towards atrial and ventricular remodelling might exert some anti-arrhythmic effect, thus reducing the risk of sudden cardiac death in these patients.",
author = "Federico Lombardi and Paolo Terranova",
year = "2003",
doi = "10.2174/1381612033454496",
language = "English",
volume = "9",
pages = "1703--1713",
journal = "Current Pharmaceutical Design",
issn = "1381-6128",
publisher = "Bentham Science Publishers B.V.",
number = "21",

}

TY - JOUR

T1 - Hypertension and concurrent arrhythmias

AU - Lombardi, Federico

AU - Terranova, Paolo

PY - 2003

Y1 - 2003

N2 - Hypertension and cardiac arrhythmias commonly coexist in many patients. In this review, we will initially discuss arrhythmogenesis in hypertension, with particular emphasis on atrial and ventricular tachyarrhythmias and sudden cardiac death, whilst in the final part, we will focus our attention on the effects of anti-hypertensive therapies on supra-ventricular and ventricular arrhythmias and on sudden cardiac death prevention. Many patients with atrial fibrillation or frequent premature ventricular contractions have hypertension, and both need to be managed appropriately. Furthermore, hypertensive left ventricular hypertrophy could cause a wide variety of ventricular arrhythmias, which could end in sudden cardiac arrest. Most anti-hypertensive therapies, such as the β-blockers or ACE inhibitors, by slowing or interrupting the progression towards atrial and ventricular remodelling might exert some anti-arrhythmic effect, thus reducing the risk of sudden cardiac death in these patients.

AB - Hypertension and cardiac arrhythmias commonly coexist in many patients. In this review, we will initially discuss arrhythmogenesis in hypertension, with particular emphasis on atrial and ventricular tachyarrhythmias and sudden cardiac death, whilst in the final part, we will focus our attention on the effects of anti-hypertensive therapies on supra-ventricular and ventricular arrhythmias and on sudden cardiac death prevention. Many patients with atrial fibrillation or frequent premature ventricular contractions have hypertension, and both need to be managed appropriately. Furthermore, hypertensive left ventricular hypertrophy could cause a wide variety of ventricular arrhythmias, which could end in sudden cardiac arrest. Most anti-hypertensive therapies, such as the β-blockers or ACE inhibitors, by slowing or interrupting the progression towards atrial and ventricular remodelling might exert some anti-arrhythmic effect, thus reducing the risk of sudden cardiac death in these patients.

UR - http://www.scopus.com/inward/record.url?scp=0042490657&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0042490657&partnerID=8YFLogxK

U2 - 10.2174/1381612033454496

DO - 10.2174/1381612033454496

M3 - Article

VL - 9

SP - 1703

EP - 1713

JO - Current Pharmaceutical Design

JF - Current Pharmaceutical Design

SN - 1381-6128

IS - 21

ER -